Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Recurrence 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Gastrointestinal Stromal Tumors 1Gastro-Intestinal Stromal Tumour 1Colorectal Neoplasms 1

Interventions

Imatinib Mesylate 10Sunitinib 4spartalizumab 2pembrolizumab 2nilotinib 2Surveys and Questionnaires 2tanespimycin 1ribociclib 1pexidartinib 1pazopanib 1olaratumab 1oblimersen 1motexafin lutetium 1masitinib 1guadecitabine 1ferric carboxymaltose 1famitinib 1epacadostat 1Surgical Procedures, Operative 1Quality of Life 1Observation 1Iron-Dextran Complex 1Indocyanine Green 1Immunoglobulin G 1Fluorescein 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Gastrointestinal Stromal Tumors × masitinib × Clear all
NCT00812240 2023-02-01

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

AB Science

Phase 3 Terminated
335 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡